AQR Capital Management - ARROWHEAD PHARMACEUTICALS IN ownership

ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 297 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q3 2021. The put-call ratio across all filers is 0.67 and the average weighting 0.3%.

Quarter-by-quarter ownership
AQR Capital Management ownership history of ARROWHEAD PHARMACEUTICALS IN
ValueSharesWeighting
Q4 2022$240,900
-68.3%
6,024
-73.8%
0.00%
-50.0%
Q3 2022$759,000
+16.4%
22,952
+17.5%
0.00%
+100.0%
Q2 2022$652,000
-87.8%
19,540
-83.2%
0.00%
-90.0%
Q1 2022$5,362,000
+67.4%
116,598
+141.3%
0.01%
+66.7%
Q4 2021$3,204,000
-10.1%
48,330
-16.1%
0.01%
-14.3%
Q3 2021$3,565,000
-3.8%
57,593
+27.5%
0.01%
+16.7%
Q2 2021$3,705,000
+115.3%
45,166
+74.0%
0.01%
+100.0%
Q1 2021$1,721,000
-37.4%
25,954
-28.1%
0.00%
-40.0%
Q4 2020$2,749,000
-10.6%
36,098
-49.5%
0.01%0.0%
Q3 2020$3,076,000
-74.6%
71,426
-75.1%
0.01%
-75.0%
Q2 2020$12,103,000
-4.0%
286,330
-34.6%
0.02%
-4.8%
Q1 2020$12,602,000
+57.4%
438,025
+247.1%
0.02%
+133.3%
Q4 2019$8,005,000
+71.0%
126,196
-24.0%
0.01%
+50.0%
Q3 2019$4,680,000
-49.8%
166,077
-52.8%
0.01%
-40.0%
Q2 2019$9,320,000
+161.9%
351,710
+81.3%
0.01%
+150.0%
Q1 2019$3,559,000
+147.0%
193,951
+67.2%
0.00%
+100.0%
Q4 2018$1,441,000
-31.7%
116,013
+5.4%
0.00%0.0%
Q3 2018$2,110,000
+20.8%
110,079
-14.3%
0.00%0.0%
Q2 2018$1,747,000
+3617.0%
128,421
+324.8%
0.00%
Q4 2016$47,00030,2320.00%
Other shareholders
ARROWHEAD PHARMACEUTICALS IN shareholders Q3 2021
NameSharesValueWeighting ↓
Aquilo Capital Management, LLC 908,474$24,410,69622.12%
Western Financial Corp/CA 820,239$22,039,82216.16%
JOHNSON & JOHNSON 247,598$6,652,9582.45%
WEALTH EFFECTS LLC 164,750$4,426,8352.19%
M28 Capital Management LP 67,400$1,811,0382.08%
Privium Fund Management B.V. 259,036$6,960,2982.07%
Evolutionary Tree Capital Management, LLC 51,266$1,377,5171.78%
Avidity Partners Management LP 1,063,897$28,586,9121.15%
SECTORAL ASSET MANAGEMENT INC 157,552$4,233,4220.82%
Vivo Capital, LLC 137,411$3,692,2340.40%
View complete list of ARROWHEAD PHARMACEUTICALS IN shareholders